PMID- 33655663
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20210705
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 26
IP  - 5
DP  - 2021 May
TI  - Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C 
      Virus Infection.
PG  - e827-e830
LID - 10.1002/onco.13739 [doi]
AB  - BACKGROUND: The safety of immune checkpoint inhibitors (ICIs) in patients with 
      hepatitis C virus (HCV) infection has not been studied in many cancers, as these 
      patients were excluded from most ICI trials. This poses a degree of uncertainty 
      when a patient with HCV is being considered for ICIs in the absence of data to 
      inform potential adverse events (AEs). MATERIALS AND METHODS: This was a 
      single-institution retrospective chart review of patients with active or resolved 
      HCV who were treated with ICIs for cancer of any type and stage from January 2012 
      to December 2019, with emphasis on AE rates. RESULTS: We identified 40 patients, 
      30 men and 10 women. Median age was 64 years. Cancer types were non-small cell 
      lung cancer (18; 45%), hepatocellular carcinoma (12; 30%), head and neck cancer 
      (4; 10%), small cell lung cancer (3; 7.5%), renal cell carcinoma (1; 2.5%), colon 
      cancer (1; 2.5%), and melanoma (12.5%). Hepatitis C was untreated in 17 patients 
      (42.5%), treated in 14 (35%), and spontaneously resolved in 9 (22.5%). AEs 
      observed were grade 3 pneumonitis in one patient (2.5%) on pembrolizumab; grade 3 
      colitis in one patient (2.5%) on nivolumab; hepatotoxicity in two patients (5%) 
      on nivolumab: one patient with grade 1 and the other with grade 2; grade 1-2 
      fatigue in three patients (7.5%); and hypothyroidism in one patient (2.5%). 
      CONCLUSION: Adverse events rates in patients with untreated and resolved HCV 
      treated with ICI for a variety of cancers were comparable with AEs rates reported 
      in clinical trials for patients without HCV. IMPLICATIONS FOR PRACTICE: The 
      safety of immune checkpoint inhibitors (ICIs) in patients with cancer with 
      hepatitis C virus (HCV) infection is a major concern because of the lack of 
      prospective safety data for most cancers. HCV is prevalent worldwide, and the 
      occurrence of cancer where ICI is indicated is not uncommon. This study was a 
      retrospective review of all patients with HCV who received ICI for a variety of 
      cancers in the authors' institution over 8 years, and the results are presented 
      in this article. The results may help inform clinical decisions and the design of 
      future clinical trials.
CI  - (c) 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf 
      of AlphaMed Press.
FAU - Alkrekshi, Akram
AU  - Alkrekshi A
AUID- ORCID: 0000-0001-7418-4883
AD  - The MetroHealth System Campus of Case Western Reserve University, Cleveland, 
      Ohio, USA.
FAU - Tamaskar, Ila
AU  - Tamaskar I
AD  - The MetroHealth System Campus of Case Western Reserve University, Cleveland, 
      Ohio, USA.
LA  - eng
PT  - Journal Article
DEP - 20210320
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - Female
MH  - Hepacivirus
MH  - *Hepatitis C/complications/drug therapy
MH  - Humans
MH  - Immune Checkpoint Inhibitors
MH  - *Kidney Neoplasms
MH  - *Lung Neoplasms/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC8100564
OTO - NOTNLM
OT  - Hepatitis C
OT  - Immune checkpoint inhibitor
OT  - Immune-related adverse events
OT  - Immunotherapy
OT  - Retrospective study
EDAT- 2021/03/04 06:00
MHDA- 2021/07/06 06:00
PMCR- 2021/05/01
CRDT- 2021/03/03 05:55
PHST- 2020/04/12 00:00 [received]
PHST- 2021/02/08 00:00 [accepted]
PHST- 2021/03/04 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2021/03/03 05:55 [entrez]
PHST- 2021/05/01 00:00 [pmc-release]
AID - ONCO13739 [pii]
AID - 10.1002/onco.13739 [doi]
PST - ppublish
SO  - Oncologist. 2021 May;26(5):e827-e830. doi: 10.1002/onco.13739. Epub 2021 Mar 20.